Guardant Health Files 8-K Regulatory Update

TL;DR

Guardant Health filed a standard 8-K, no major news.

AI Summary

Guardant Health, Inc. filed an 8-K on July 29, 2024, to report other events and financial statements. The filing does not contain specific details about new agreements, acquisitions, or significant financial changes, but serves as a standard regulatory update.

Why It Matters

This filing is a routine disclosure required by the SEC for public companies, indicating that Guardant Health has made a regulatory filing without disclosing specific material events.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for other events and financial statements, not indicating any immediate material changes or risks.

Key Numbers

• 20240729 — Filing Date (Date of report)

Key Players & Entities

• Guardant Health, Inc. (company) — Registrant
• 001-38683 (company) — SEC File Number
• 45-4139254 (company) — IRS Employer Identification No.
• 3100 Hanover Street Palo Alto, California 94304 (company) — Principal Executive Offices Address
• 855 - 698-8887 (company) — Registrant's telephone number

FAQ

From the Filing

0001193125-24-186674.txt : 20240729 0001193125-24-186674.hdr.sgml : 20240729 20240729064630 ACCESSION NUMBER: 0001193125-24-186674 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20240729 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240729 DATE AS OF CHANGE: 20240729 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Guardant Health, Inc. CENTRAL INDEX KEY: 0001576280 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 454139254 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38683 FILM NUMBER: 241148790 BUSINESS ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 BUSINESS PHONE: 855-698-8887 MAIL ADDRESS: STREET 1: 3100 HANOVER STREET CITY: PALO ALTO STATE: CA ZIP: 94304 8-K 1 d869952d8k.htm 8-K 8-K false 0001576280 0001576280 2024-07-29 2024-07-29     UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549     FORM 8-K     CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): July 29, 2024     GUARDANT HEALTH, INC. (Exact name of registrant as specified in its charter)       Delaware   001-38683   45-4139254 (State or other jurisdiction of incorporation or organization)   (Commission File Number)   (IRS Employer Identification No.) 3100 Hanover Street Palo Alto , California 94304 (Address of principal executive offices) (Zip Code) 855 - 698-8887 (Registrant’s telephone number, include area code)     Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:   ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)   ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)   ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))   ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:   Title of each class   Trading Symbol(s)   Name of each exchange on which registered Common Stock, $0.00001 par value per share   GH   The Nasdaq Global Select Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐       Item 8.01 Other Events. On July 29, 2024, Guardant Health, Inc. (the “Company”) issued a press release announcing that the U.S. Food and Drug Administration’s (the “FDA”) has approved the Company’s Shield blood test to screen for colorectal cancer in adults age 45 and older who are at average risk for the disease. A copy of the press release is being filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.   Item 9.01. Financial Statements and Exhibits. (d) Exhibits.   Exhibit No.    Description 99.1    Press release of Guardant Health, Inc., dated July 29, 2024. 104    Cover Page Interactive Data File (embedded within the Inline XBRL d